🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchSURMOUNT-MMO: tirzepatide for morbid obesity — anyone have experience? Page 5

SURMOUNT-MMO: tirzepatide for morbid obesity — anyone have experience?

jason_paloalto Wed, Feb 18, 2026 at 8:14 AM 22 replies 986 viewsPage 5 of 5
A1cHero_PHX
Member
523
2,678
Jul 2024
Phoenix, AZ
Feb 20, 2026 at 7:13 AM#21
Dr.CardioMD said:
The useful move here is to separate what is established from what is widely repeated.

Coming at Dr.CardioMD’s question from a different direction. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

Last edited: Feb 20, 2026 at 12:13 PM
47 20zoe_NC, Dr.ObesityLA, NurseKim_ATL and 44 others
Reply Quote Save Share Report
hank_denver
Member
278
1,234
Sep 2024
Denver, CO
Feb 20, 2026 at 7:15 PM#22

Adding the numbers, since they settle part of this. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

48 21raj_cambridge, ingrid_STO, pete_nash and 45 others
Reply Quote Save Share Report
JakeBK_lifts
Member
523
2,345
Jul 2024
Brooklyn, NY
Feb 21, 2026 at 7:17 AM#23

One thing that is still open after Dr.CardioMD’s answer:

How would you tell the difference between that and the alternative explanation?

49 22LabKate, kate.chem, DataDave and 46 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
PurityPaulOR
Senior Member
1,890
7,890
Mar 2024
Oregon
Feb 21, 2026 at 7:18 PM#24
hank_denver said:
Practical: whatever you change, write down the date and the reason.

Worth saying that the confident version of this is more useful to the person writing it than to the person reading it.

Last edited: Feb 21, 2026 at 10:18 PM
50 23Dr.Martinez, mike_mod, SarahChen_PharmD and 47 others
Reply Quote Save Share Report
maya_sedona
Member
289
1,234
Sep 2024
Sedona, AZ
Feb 22, 2026 at 7:19 AM#25
hank_denver said:
Practical: whatever you change, write down the date and the reason.

That is right for the common case. Whether it is right for the case being asked about depends on a detail that has not been given.

Last edited: Feb 22, 2026 at 11:19 AM
1 24Dr.RaviCardio
Reply Quote Save Share Report
1345

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register